Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist, Pre-clinical NGS

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Aug 30, 2022

View more

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How you will Achieve More with Intellia:

As a Scientist, you will support the characterization and quantitation of gene editing events using high throughput next-generation sequencing (NGS). You will be a part of the Pre-clinical NGS Platform team, focused on genomic characterization assays for regulatory packages and clinical programs with expertise in NGS and working in a high throughput environment. Main responsibilities include:

  • Support both in vivo and ex vivo programs for genotoxicity studies, including experimental design, execution, data interpretation, and study report writing for regulatory filings.

  • Execute high throughput, SOP-driven, NGS library preparation workflows both manually and using liquid handling automation.

  • Develop novel NGS assays for on-/off-target editing characterization.

  • Optimize NGS workflows and operate Illumina sequencers.

  • Write and QC technical and study reports to support regulatory filings (IND or CTA equivalent), and then synthesize the results for effective communication across various levels of expertise

About You:

We are looking for a candidate with a Ph.D. with 0-2 years, or a BS/MS with 10/8+ years in Molecular Biology, Genetics, Cell Biology or related discipline, with relevant experience in an academic or industrial setting. If you have strong communications skills (written and oral), coupled with exceptional time management skills, attention to detail, and a team-centric attitude - We encourage you to apply!

  • Solid hands-on experience in DNA/RNA sequencing library preparation, quantification, and sequencing using Illumina sequencing platforms.

  • Experience with molecular and cellular assays (DNA/RNA extraction, PCR, qPCR, ddPCR, etc.)

  • Experience with NGS assay development is preferred.

  • Extensive Knowledge in gene editing approaches and Genomics is preferred.

  • Experience with long-read sequencing is a plus.

  • Experience with mammalian cell culture, transfection or transduction using LNP, AAV is a plus.

  • Experience with liquid handling platforms (preferably Hamilton) is preferred.

Meet your future team:

The Genomics team is a fun, energetic, and passionate group of individuals, who are focused on pre-clinical NGS data support for IND or CTA packages. You will report directly to the Director of the Pre-clinical NGS team. This hiring manager oversees Intellia’s regulatory data generation for genotoxicity studies. Given the breadth of work on this team, the candidate will have the opportunity to explore a wide range of areas within the Automation, Engineering, Genomics, Informatics, and Screening (AEGIS) group.

The team is currently working mostly onsite to execute NGS workflows in a wet-lab environment. Therefore, we require a candidate to be currently local to Cambridge MA, or open to relocating. While much of the day-to-day operations require managing wet-lab work, our team is focused on building not just technical expertise but fostering an environment for the growth of young scientists interested in a career in RNA-biotech. If you join our team, you can expect to join a hardworking, collaborative but flexible environment. We look forward to fostering your skills, learning from your experiences, and building a larger team that will make a difference in patients' lives.

Covid-19 Vaccination Policy: All Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. This requirement includes a booster dose once eligible. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert